With the announcement of a lead vaccine candidate for COVID-19, Johnson & Johnson is committed to providing one billion vaccines worldwide for emergency use!
Johnson & Johnson began as a small firm that was created in 1886 to make surgical dressings and has become one of the world’s largest healthcare companies for providing pharmaceutical, consumer, and medical devices.
With more than 250 subsidiary companies, the company sells its products in more than 175 countries. Since the COVID-19 outbreak, Johnson & Johnson has been jointly working with various health centers to put a full stop on the fast-moving COVID-19 pandemic.
On March 30, Johnson &Johnson announced a lead SARS-CoV-2 vaccine candidate identification with tow back-ups. Since January 2020, work will progress into Phase1/2, a clinical trial in the second half of July 2020.
Initially, for emergency use, the first batch of the Johnson and Johnson COVID 19 Vaccine is expected to be available in early 2021.
The Janssen Pharmaceutical has supported the manufacturing of the lead investigational SARS-CoV-2 vaccine candidate with collaborations with Emergent BioSolutions, Inc. and Catalent Biologics.
Johnson and Johnson’s efforts boosted to bring the SARS-CoV-2 vaccine by the collaboration between Biomedical Advanced Research and Development Authority (BARDA) and Janssen Pharmaceutical Companies of Johnson & Johnson. BARDA is a part of the U.S Department of Health &Human Services, and the Beth Israel Deaconess Medical Center (BIDMC). Earlier also, the company has partnered with BARDA to prepare for an influenza pandemic. This commitment to BARDA is to develop a COVID-19 vaccine, conduct clinical trials, and support the up scaling of production. The company’s partnership is also a step towards bringing treatment for COVID-19 for the patients who are already infected.
In the race of bringing COVID-19 Vaccine, the process usually takes years on testing and getting approval. On March 30, the company announced the lead candidate for a vaccine against COVID-19 and will make it into a phase 1 human clinical trial by September of 2020, said by Dr. Richard Nettles, MD of Janssen Infectious Diseases.
The vaccine and drug development involve a series of large human clinical trials. Trails start among phase 1 clinical trial with a small number of people moving to phase 2 clinical trials with an average number of people and, lastly, with a large number of experiments in phase 3 clinical trials. In this case, the company remained focused on accelerating and production as quickly as possible for them.
To what number of vaccines does Johnson & Johnson plan to produce?
Johnson & Johnson works with a motive to improve the access and affordability of their products to create healthier communities around. The plan is to produce up to a billion doses of vaccine and, if required, will try to provide 600 million doses by the end of the year.
Dr. Nettles said,
“Johnson & Johnson would love to partner with various local and international government and private companies to bring the vaccine for the needy patients.”